Project Grant R21AI186928
Award Date
8/20/24
Completion Date
7/31/26
Dollars Obligated
$167K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,350,312 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Los Angeles (UCLA) to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The project aims to create and optimize novel fluorescent trehalose probes that can detect live Mycobacterium tuberculosis and assess drug resistance, addressing critical limitations...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $817,252 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center (VUMC) to conduct a study entitled "Investigating Multiple PK and PD Relationships for TB-HIV (IMPPROVE TB-HIV)". This 1-year project aims to leverage VUMC's Tuberculosis Sentinel Research Network to perform pharmacokinetic-pharmacodynamic (PK-PD) analyses on first-line...
This Project Grant award of $209,750 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to leverage antibody-based "omics" approaches to prevent and detect tuberculosis (TB) in children affected by HIV. The key objectives are to: Define antibody Fc (fragment crystallizable) features associated with protection from Mycobacterium tuberculosis (MTB) infection in infants with and without...
This $162,000 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The Washington University, the grant recipient, will leverage their mouse model of MTB infection to quantify pDC lung trafficking, identify the chemokine receptor required for pDC lung...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,413,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute to study mechanisms for controlling Mycobacterium tuberculosis (MTB) infection in the lungs. The project aims to understand the immune responses generated by an attenuated, live-replicating MTB strain that has demonstrated protective efficacy in non-human primate models....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $813,373 in funding to Rutgers, The State University of New Jersey to conduct research on developing new classes of pyrazinoic acid prodrugs against pyrazinamide-resistant Mycobacterium tuberculosis. The key goals of this 5-year research project are to characterize the diverse set of Mycobacterium tuberculosis amidases...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $193,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on August 20, 2024. The award will fund a 5-year research project titled "The Relationship Between HIV Exposure, Contact Networks, and TB in Children Under 5 Years Old." As part of this project, BMC will collaborate with Stellenbosch University in South Africa, which...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,200 to study the mechanisms of interferon-gamma (IFN-γ)-independent T cell and B cell-mediated protection against tuberculosis (TB) in humans. The research aims to elucidate the IFN-γ-independent T cell response and characterize the B cell, antibody, and T follicular helper (Tfh) cell responses in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,516 to Vanderbilt University Medical Center to conduct pharmacokinetic assessments of short-course rifapentine for tuberculosis (TB) preventive therapy in people living with HIV taking dolutegravir, children under 12 years, and pregnant women. The project aims to confirm that model-informed dosing of TB and HIV...
This $737,342 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to improve the detection and study of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: 1) Develop new imaging technologies capable of detecting single MTB bacteria in vitro and in vivo; 2) Use...